GABAA-Modulating Steroid Compounds for Brain Excitability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that can modulate brain excitability and treat CNS-related disorders, as existing therapies like benzodiazepines and barbiturates have limitations and new neuroactive steroids are required to address these conditions.
Innovation Solution
Development of compounds designed as GABA modulators, including specific formulas and their pharmaceutically acceptable salts, which can act as therapeutic agents for treating CNS-related disorders by modulating the GABAA receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies like benzodiazepines and barbiturates are used to treat CNS disorders, then brain excitability can be modulated, but therapeutic limitations and side effects occur
Solution Approach 1:
The patent modifies the chemical structure of neuroactive steroids by changing parameters such as substituting groups at specific positions (e.g., 21-hydroxy substitution, 17-alpha-alkyl groups) to optimize therapeutic efficacy while reducing side effects associated with existing benzodiazepine and barbiturate therapies
2Reliability
If new neuroactive steroids are developed to overcome limitations of existing therapies, then therapeutic benefits improve, but complexity of compound development increases
Solution Approach 1:
The patent divides the complex task of developing new neuroactive steroids into a systematic series of analogs with specific structural modifications, allowing for methodical optimization of therapeutic properties while managing development complexity through structured chemical series
Solution Approach 2:
The patent systematically varies chemical parameters (substituent groups, molecular weight, lipophilicity) across a series of steroid analogs to achieve desired therapeutic effects while maintaining manageable structural complexity through defined modification patterns
3Adaptability or versatility
If compounds are designed to specifically modulate GABAA receptor, then selectivity for CNS disorders improves, but difficulty of achieving desired selectivity increases
Solution Approach 1:
The patent introduces specific local modifications at key positions of the steroid molecule (e.g., 21-position hydroxy group, 17-alpha position substituents) to enhance binding affinity and selectivity for the GABAA receptor, thereby achieving desired receptor specificity through localized structural optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat CNS-related disorders such as depression, schizophrenia, and seizure activity by modulating brain excitability, providing therapeutic and prophylactic benefits.
Implementation Method 1
GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell
Data Source
AI summary
Provided herein is a compound of Formula (I-I)or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.